



# The Efficacy of Carbon Dioxide Paste in Alleviating Pain in Patients After Neck Dissection: Protocol for a Double-Blinded, Randomized Controlled Trial

Tadokoro, Yoshiaki ; Takeda, Daisuke ; Saito, Izumi ; Yatagai, Nanae ;  
Takei, Yasumasa ; Akashi, Masaya ; Hasegawa, Takumi

---

(Citation)

JMIR Research Protocols, 12:e50500

(Issue Date)

2023-11-13

(Resource Type)

journal article

(Version)

Version of Record

(Rights)

©Yoshiaki Tadokoro, Daisuke Takeda, Izumi Saito, Nanae Yatagai, Yasumasa Takei, Masaya Akashi, Takumi Hasegawa.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction ...

(URL)

<https://hdl.handle.net/20.500.14094/0100485288>



Protocol

# The Efficacy of Carbon Dioxide Paste in Alleviating Pain in Patients After Neck Dissection: Protocol for a Double-Blinded, Randomized Controlled Trial

Yoshiaki Tadokoro, DDS; Daisuke Takeda, DDS, PhD; Izumi Saito, DDS, PhD; Nanae Yatagai, DDS, PhD; Yasumasa Kakei, DDS, PhD; Masaya Akashi, DDS, PhD; Takumi Hasegawa, DDS, PhD

Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, Japan

**Corresponding Author:**

Takumi Hasegawa, DDS, PhD

Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine

7-5-1, Kusunoki-cho, Chuo-ku

Kobe, 6500017

Japan

Phone: 81 78 382 6213

Email: [hasetaku@med.kobe-u.ac.jp](mailto:hasetaku@med.kobe-u.ac.jp)

## Abstract

**Background:** Head and neck cancers that cause severe aesthetic and functional disorders normally metastasize to the cervical lymph nodes. Patients with cervical lymph node metastasis are undergoing neck dissection. Shoulder complaints are common after neck dissection, with patients reporting symptoms such as pain, weakness, shoulder droop, and disability. However, no safe and effective treatment is available for this condition at present. We will conduct a double-blinded, randomized controlled trial to evaluate the efficacy of carbon dioxide (CO<sub>2</sub>) paste in relieving pain in patients after neck dissection.

**Objective:** This will be the first clinical study to compare the efficacy of CO<sub>2</sub> paste with placebo in relieving postoperative pain in patients who underwent neck dissection.

**Methods:** We will perform this trial at the Kobe University Hospital in Japan. Patients will be randomized 1:1 into the CO<sub>2</sub> paste and control groups. Patients in the CO<sub>2</sub> paste group will have the CO<sub>2</sub> paste applied to the cervical surface skin for 10 minutes once per day for 14 consecutive days. The primary end point of the study is a change in the visual analog scale (VAS) scores of neck pain from baseline on day 1 (preapplication) to the end of drug application (day 15). Secondary end points include changes in the following parameters from baseline on day 1 to the end of drug application (day 15) or the study (day 29): neck pain VAS score (days 1-29), grip strength (days 1-15 and 1-29), VAS scores for subjective symptoms (the feeling of strangulation, numbness, swelling, and warmth in the neck and shoulder region) for days 1-15 and 1-29, whether the VAS score improved more than 30% (days 1-15), the arm abduction test (days 1-15 and 1-29), shoulder range of motion (abduction and flexion) for days 1-15 and 1-29, occurrence of skin disorders, and occurrence of serious side effects. Periodic monitoring will be conducted for participants during the trial. This study was approved by the certified review board of Kobe University.

**Results:** The intervention commenced in May 2021 and will continue until March 2024. The collected data will provide information on the efficacy of the CO<sub>2</sub> paste treatment. The primary end point will be compared using the Wilcoxon test, with the 1-sided significance level set at 5%. Each evaluation item will be summarized. Secondary efficacy end points will be analyzed to provide additional insights into the primary analysis. Findings based on the treatment effects are expected to be submitted for publication in 2025.

**Conclusions:** This trial will provide exploratory evidence of the efficacy and safety of CO<sub>2</sub> paste in relieving pain in patients after neck dissection.

**Trial Registration:** Japan Registry of Clinical Trials (jRCT) identifier: jRCTs051210028; <https://jrct.niph.go.jp/en-latest-detail/jRCTs051210028>

**International Registered Report Identifier (IRRID):** DERR1-10.2196/50500

(*JMIR Res Protoc* 2023;12:e50500) doi: [10.2196/50500](https://doi.org/10.2196/50500)

**KEYWORDS**

carbon dioxide; double-blind; neck dissection; pain; paste; postoperative; randomized controlled trial; surgery; surgical

**Introduction**

Postoperative wound pain in the head and neck region generally improves within 1-2 weeks after surgery. However, patients undergoing cancer treatment often experience continuous, persistent pain, which can cause physical and psychological distress. Surgery and radiation therapy often cause painful scarring and contractures. Musculoskeletal and neuromuscular disabilities after radiotherapy and surgical treatment are major causes of cancer treatment-related side effects. Disabilities in the head and neck region after cancer treatment are related to a patient's ability to communicate, eat, and work [1]. These changes reduce the functioning and social interaction of these patients [1,2].

Shoulder complaints are common (18%-77%) after neck dissection, even if the spinal accessory nerve has been preserved [3,4]. Symptoms such as pain, weakness, shoulder droop, and disability have been reported in patients after neck dissection [5,6]. Pain is an important factor affecting the quality of life (QOL) of cancer survivors [1,7]. Although various drug treatments are available for preventing or improving the management of chronic postsurgical pain [8-10], these treatments have side effects.

The exact etiology of persistent postsurgical pain remains unclear, but its causes are thought to involve neuropathy [11-13], inflammation [14,15], central sensitization [16,17], and ischemia [18-20]. In rats, decreased blood flow and tissue ischemia cause complex regional pain syndrome-like symptoms [18]. In addition, patients with peripheral arterial diseases experience chronic ischemic pain [20]. Thus, continuous postoperative pain may be reduced by improving the blood flow in the ischemic scar tissue.

We had previously reported the effects of transcutaneous application of carbon dioxide (CO<sub>2</sub>) in a hydrogel as an absorption-promoting agent in healthy individuals and various animal models [21-23]. Transcutaneous application of CO<sub>2</sub> improves vascularization and exercise performance in rats; it also increases local oxygenation, causing the dissociation of oxygen from hemoglobin (Bohr effect) [23-25]. However, this method uses CO<sub>2</sub> gas, which is difficult to apply to the head and neck. In a recent study, we investigated the usefulness, safety, and feasibility of a CO<sub>2</sub> paste by analyzing the changes in blood flow in a phase 1 clinical study in healthy individuals [26]. The CO<sub>2</sub> paste reacted with water on the skin surface, could infiltrate CO<sub>2</sub> transcutaneously without the use of external CO<sub>2</sub> gas, and could be applied to the head and neck region. In the phase 1 clinical study, application of the CO<sub>2</sub> paste increased

the blood flow in the skin and muscles, as observed by dynamic magnetic resonance imaging, and caused no adverse reactions.


This double-blind, randomized controlled trial aims to evaluate the efficacy and safety of CO<sub>2</sub> paste in decreasing postoperative neck pain in patients undergoing neck dissection.

**Methods****Objectives**

This study will examine whether the application of a CO<sub>2</sub> paste can reduce postoperative neck pain in patients receiving neck dissection in a double-blinded, randomized controlled trial. The primary objective is to estimate the within-patient differences in visual analog scale (VAS) scores for neck pain ranging from 0 (no pain) to 10 (worst pain) from baseline (day 1: before application) to the end of the study drug application (day 15). The secondary objectives are to evaluate the within-patient differences in the VAS scores for neck pain from baseline (day 1: before application) to the end of study drug application (day 15), grip strength from baseline to the end of the drug application (days 1-15) and the end of the study period (days 1-29), VAS scores for subjective symptoms (the feeling of strangulation, numbness, swelling, and warmth) from baseline to the end of the drug application (days 1-15) and the end of the study (days 1-29), arm abduction [27] from baseline to the end of the drug application (days 1-15) and the end of the study (days 1-29), and shoulder joint range of motion (abduction or flexion) from baseline to the end of the drug application (days 1-15) and the end of the clinical study (days 1-29). In addition, we aim to evaluate whether patients showed a ≥30% improvement in the VAS scores for neck pain from baseline to the end of the drug application (days 1-15) and the end of the study (days 1-29).

**Study Design**

This study has been designed as a single-center, placebo-controlled, double-blind, randomized controlled trial. The patient flowchart is shown in Figure 1. This study will be conducted at Kobe University Hospital. All data will be stored and archived at the data center of Kobe University Hospital. We will use Research Electronic Data Capture (REDCap; Vanderbilt University), an electronic data system for clinical research, to manage the data and protect confidentiality before, during, and after the trial. The study population will consist of patients undergoing neck dissection and will be selected based on the inclusion and exclusion criteria listed in Textbox 1. Patients will be recruited from Kobe University Hospital from May 24, 2021, to March 31, 2024. All patients will be asked if they wish to participate in the study and will be enrolled after obtaining written informed consent.

**Figure 1.** Flowchart of participants. VAS: visual analog scale.

**Textbox 1.** Inclusion and exclusion criteria for the study.

<p><b>Inclusion criteria</b></p> <ul style="list-style-type: none"><li>• Aged 20 years or older</li><li>• Have complaints of postoperative neck pain after unilateral cervical dissection</li><li>• Between 6 months and 3 years after neck dissection</li><li>• A visual analog scale score of 1 or higher for neck pain</li><li>• Have given voluntary consent to participate in this clinical study</li></ul> <p><b>Exclusion criteria</b></p> <ul style="list-style-type: none"><li>• Hypersensitivity to drugs, including severe allergies</li><li>• Peripheral arterial disease, ischemia (Fontaine III-IV), and ischemic cerebral artery disease</li><li>• Heart failure (New York Heart Association IV) and ischemic heart disease (Canadian Cardiovascular Society functional classification 3-4)</li><li>• Female patients who are pregnant, lactating, wishing to become pregnant during the study period, or are fertile and cannot accept an effective contraceptive method</li><li>• Severe respiratory disease with oxygen saturation (SpO2) less than 90% at rest</li><li>• Skin ulcers larger than 4 cm × 4 cm × 1 cm or skin diseases making it difficult to apply the paste</li><li>• Deemed inappropriate for participation in this clinical study by the investigators</li></ul>
---

**Randomization (Allocation)**

Using the permutation random block method stratified by category, participants will be randomly assigned to either the CO<sub>2</sub> paste group or the placebo control group at a 1:1 allocation ratio. To ensure that blinding is maintained, the block size will not be disclosed. The allocation sequence for the randomization method will be generated by a biostatistician. All participants who provide consent to participate, fulfill the inclusion criteria, and do not meet any of the exclusion criteria will be randomized. The eligibility of each participant will be confirmed. A subject-enrollment confirmation form containing the eligibility judgment, randomization assignment results from the generated random sequence, and the enrollment number will be issued.

**Experimental Drugs**

The CO<sub>2</sub> paste (direCO<sub>2</sub>t) is manufactured as an experimental drug at the CO2TECH, a limited liability company. The CO<sub>2</sub> paste contains 1,3-butylene glycol and other components, including sodium hydrogen carbonate, malic acid, sodium dihydrogen phosphate, an alkyl-modified carboxyvinyl polymer, and carboxyvinyl polymer. The placebo paste is a formulation in which the sodium bicarbonate in the CO<sub>2</sub> paste is replaced by a nonreactive material (sodium chloride).

**Treatment and Assessment Schedule**

Within 4 weeks of enrollment, the VAS score for neck pain will be evaluated 1 week before the administration of the experimental drug during the preobservation period. On the first day of treatment, body temperature, blood pressure, oxygen saturation, and pulse rate will be measured by a physician, dentist, or nurse before and after the application of the experimental drug. The paste will be applied at 0.2 g-0.3 g/100 cm<sup>2</sup> to the affected neck area once per day for 14 consecutive days. The duration of each application will be 10 minutes, and the paste will be wiped off after application.

**Data Collection**

The data collection schedules are presented in Table 1. The primary investigator or subinvestigator will enter the case report form (CRF) data for each participant into the electronic data capture (EDC) system. The principal investigator will confirm that the entered CRF data are complete and correct, electronically sign the CRF on the EDC system, and print out the signed CRF for filing. The CRF printout will be retained. If any queries about the CRF data are entered by the staff at the data center, the primary investigator or subinvestigator will be required to promptly respond to them.

**Table 1.** Data collection schedule.

	Registration (within 4 weeks before allocation)	Preobserva- tion (7±3 days before alloca- tion)	Allocation day 1 (preapplica- tion)	Allocation day 1 (postapplica- tion)	Postallocation day 15+1 (finish application)	Postalloca- tion day 29+3	Exclusion	Within 7 days after exclusion
Assessment of eligi- bility criteria	✓							
Obtain consent	✓							
Registration	✓							
Patient characteris- tics <sup>a</sup>	✓							
Allocation and start of the application			✓					
VAS <sup>b</sup> of neck pain		✓	✓	✓	✓	✓		
VAS values of sub- jective symptoms <sup>c</sup>			✓	✓	✓	✓		
Strength of grip arm abduction test <sup>d</sup>			✓		✓	✓		
Shoulder joint range of motion (abduction or flexion)								
Adverse events				✓	✓	✓	✓	✓
Vital sign <sup>e</sup>	✓		✓	✓	✓		✓	✓
Oxygen saturation (SpO <sub>2</sub> )	✓		✓				✓	✓
Confirmation of days of application					✓		✓	

<sup>a</sup>Sex, date of birth, age, medical history, comorbidity, primary disease, TNM classification, the number of days after surgery, the range of neck dissection, preservation of sternocleidomastoid muscle, accessory nerve, and internal jugular vein, and the details of adjuvant therapy.

<sup>b</sup>VAS: visual analog scale.

<sup>c</sup>Strangulation, numbness, swelling, and warmth.

<sup>d</sup>Arm abduction test: up to 180° without pain or effort (5 points), up to 180° but with pain or effort (4 points), up to more than 150° but less than 180° (3 points), up to more than 90° but not less than 150° (2 points), up to approximately 90° (1 point), and up to less than 90° (0 point) [27].

<sup>e</sup>Body temperature, blood pressure, and pulse rate.

## Main Outcomes

The primary end point for efficacy is the change in the VAS score for neck pain from baseline (day 1: before application) to the end of the study drug application (day 15).

The secondary efficacy end points are as follows:

1. Change in the VAS score for neck pain from baseline (day 1: before application) to the end of the clinical study (day 29).
2. Changes in grip strength from baseline to the end of the drug application (days 1-15) and the end of the study (days 1-29).
3. Changes in VAS scores for subjective symptoms (feeling of strangulation, numbness, swelling, and warmth) from baseline to the end of the drug application (days 1-15) and the end of the study (days 1-29).

4. Whether the VAS score for neck pain showed a  $\geq 30\%$  improvement from baseline to the end of the drug application (days 1-15) and the end of the study (days 1-29).
5. Change in arm abduction [27] from baseline to the end of drug administration (days 1-15) and the end of the study (days 1-29).
6. Change in shoulder joint range of motion (abduction and flexion) from baseline to the end of drug application (days 1-15) and the end of the study (days 1-29).

The secondary end point for safety is the presence or absence of adverse events such as skin disorders and serious diseases. The relationships among the interventions, outcomes, other assessments, and visits associated with the participants in this study are shown in Table 1.

## Statistical Analysis

The primary objective of this clinical study was to evaluate the efficacy of the CO<sub>2</sub> paste versus the placebo in terms of the change in VAS scores for neck pain (the primary end point).



For the comparison of the primary end point, the Wilcoxon test will be performed for the null hypothesis, “There is no difference in the change in VAS values for neck pain at day 15 between the placebo group and the CO<sub>2</sub> paste group.” The significance level will be set at 5.0% (1-sided). Each evaluation item will be summarized. Secondary efficacy end points will be analyzed to provide additional insights into the primary analysis. No adjustment for multiplicity will be made in the analyses of the secondary efficacy end points. The significance level for hypothesis testing is 5% (2-sided) with 2-sided 95% CIs. The incidence and rate of disease will also be evaluated. The safety end point is the frequency of the occurrence of adverse reactions. Tables will be prepared for the end points, and exact 2-sided 95% CIs of the binomial distribution will be calculated for each group to estimate the proportions.

### Sample Size Calculation

Most patients are expected to have a baseline VAS score of 2–3 cm. For the primary end point (the amount of change in VAS values for neck pain), we estimated that the mean difference in change between the CO<sub>2</sub> paste application and placebo groups would be 2 (SD 1.5) cm. A Wilcoxon test (a nonparametric test) will be performed considering the possibility that participants with a baseline score of less than 2 cm might be enrolled. The number of cases based on the Wilcoxon test can be calculated by multiplying the number of cases based on the *t* test [28]. Although the constant for multiplication is 1.045 in the case of a normal distribution, since the participants in this study were not assumed to be normally distributed, the number of cases was calculated by multiplying by 1.2. When conducting a *t* test with a 1-sided significance level of 5.0% and a power of 80%, a total of 7 participants were required per group. When the number of cases was multiplied by 1.2, the total number of cases was 8.4. Therefore, considering drop out cases, 20 cases would be sufficient to maintain power.

### Monitoring for Human Rights, Safety, and Adequacy

Monitoring will be conducted periodically to check whether the human rights and safety of the participants are protected and to confirm that the regulatory requirements of the Clinical Trials Act are followed. To ensure an appropriate assessment, the principal investigator is responsible for dealing with personal data and items specified in the written procedure. Any requirements made by the ethics committee will be immediately announced to the participants by the study investigators.

### Other Considerations

This study will be conducted without patient or public involvement. Neither the patients nor the public will be involved in the development of the research question, study design, or implementation of the trial. Patients will not be invited to develop patient-relevant outcomes, interpret the results, or participate in the writing or editing of the final manuscript. Since the interventions in this study are routine clinical procedures, the burden of the interventions will be assessed by the patients themselves.

Any protocol changes that affect the study conduct or participant risk-benefit profile will require approval from the relevant institutional review board, including changes in the objectives,

design, sample size, participant characteristics, staff changes, or significant administrative features. Minor protocol corrections or clarifications that do not affect the study conduct or the participant risk-benefit profile will be viewed as administrative changes and documented internally. The study investigators will have full access to and ownership of all the data. Anonymized data will be made available to other interested investigators for additional analyses on reasonable request, following reports of primary outcomes and with an appropriate data use agreement. The findings of this study will be disseminated through scientific and professional conferences and a peer-reviewed journal.

### Ethical Considerations

The study is being conducted in compliance with the principles of the Declaration of Helsinki (1996), the principles of good clinical practice, and all applicable regulatory requirements. This study has been approved by the Clinical Research Review Board of Kobe University (CRB5180009), and the trial has been registered with the Japan Registry of Clinical Trials (jRCT) (jRCTs051210028). All participants will be required to provide written informed consent before any study procedures are conducted. The participants will have the opportunity to review the consent form and confirm that they have fully understood the details of the study procedures. Secondary use of the data will occur only if the patients provide written informed consent for additional use of their data. Secondary use of the data will adhere to appropriate ethical review and approvals, as per institutional guidelines. No funding was received for this study, including institutional or departmental support. The study is not commissioned, externally peer reviewed.

## Results

The subject recruitment began on May 24, 2021. The entry period for participants is up to March 31, 2024, three years after the jRCT registration. Data analyses of all enrolled participants will be conducted in 2024. This manuscript is based on the current version of the protocol (version 3.0), last updated on December 23, 2022.

The data sets generated in this study will be available on the jRCT website. The final report is expected to be published in a peer-reviewed journal in 2025. The findings will be disseminated through scientific and professional conferences and peer-reviewed journal publications in 2025.

## Discussion

### Expected Findings and Implications

This report describes the protocol for a study evaluating the application of CO<sub>2</sub> paste to patients who undergo neck dissection and experience postoperative complaints. A neck dissection is a surgical procedure performed to remove cervical lymph nodes. During surgery, the blood vessels are ligated to prevent bleeding. In addition, the internal jugular vein, which drains blood from important organs such as the brain, face, and neck, is removed depending on the type of neck dissection. These blood flow interruptions lead to wound ischemia and various postoperative symptoms or dysfunctions.

Pain, the main side effect of neck dissection, often aggravates patient QOL [1,7]. As its pathogenesis remains uncertain, a treatment strategy for postoperative pain has not yet been established. Analgesics such as nonsteroidal anti-inflammatory drugs and acetaminophen are commonly administered to relieve this pain. Nonsteroidal anti-inflammatory drugs show remarkable efficacy as painkillers; however, they are also associated with serious adverse reactions in the gastric mucosa and cardiovascular, hepatic, renal, and hematological systems [29]. Although almost all patients receive acetaminophen [30], those undergoing neck dissection continue to experience pain. Considering the limitations of drug therapy, effective treatment of every patient with postoperative pain is essential.

In a phase 1 clinical study, we reported that CO<sub>2</sub> paste application increases blood flow to the skin and muscles without any side effects [26]. Since transcutaneous CO<sub>2</sub> application induces angiogenesis by inducing an artificial Bohr effect, we hypothesize that this simple and adaptable treatment can alleviate side effects and improve the QOL of patients undergoing neck dissection.

This study will be the first to apply CO<sub>2</sub> paste to postoperative skin. Since it is composed of food ingredients, the CO<sub>2</sub> paste is considered to have few life-threatening side effects. However, there is no evidence on whether its application may induce dermatitis. Therefore, the occurrence of dermopathies such as erythema and exanthema should be carefully monitored during the trial. To address potential safety concerns, the CO<sub>2</sub> paste will be applied to the postoperative neck for only 10 minutes a day.

Through this study, we aim to determine the curative effect of CO<sub>2</sub> paste application on postoperative neck pain in patients

undergoing neck dissection. Since the efficacy of CO<sub>2</sub> paste for neck pain has never been reported, this will be the first well-designed clinical evaluation study on this topic. Our primary hypothesis is that CO<sub>2</sub> paste application can reduce pain in patients undergoing neck dissection. We also expect that the application of this paste will reduce subjective symptoms, including feelings of strangulation, numbness, swelling, and warmth, and will improve grip strength, arm abduction, and shoulder joint range of motion (abduction and flexion).

### Study Strengths and Limitations

We previously conducted a clinical trial on a small number of healthy individuals. To explore the adequacy and applicability of CO<sub>2</sub> paste application, this will be the first protocol to be performed as a phase 2, double-blinded, randomized controlled trial, evaluating the efficacy of CO<sub>2</sub> paste in a small number of patients with neck pain after neck dissection. Nonetheless, this clinical trial has some limitations that should be acknowledged. First, the number of evaluated patients is relatively small to conclusively determine the efficacy of the CO<sub>2</sub> paste. Second, since some patients underwent neck dissection as part of larger resections, a small amount of heterogeneity is expected. Finally, this study is limited by its short duration (28 days).

### Conclusions

Considering the general condition of the patients and the side effects of drug therapy, postoperative pain after neck dissection is difficult to manage. Therefore, establishing a widely applicable treatment with fewer adverse effects is essential. The results of this study will provide valuable evidence for the future application of CO<sub>2</sub> paste to patients complaining of pain after neck dissection.

### Acknowledgments

This trial is supported by CO2TECH, a limited liability company, which has provided the authors with both the CO<sub>2</sub> and the placebo paste. We would like to thank Editage for English language editing.

### Data Availability

The data sets generated or analyzed during this study are available from the corresponding author on reasonable request.

### Authors' Contributions

All authors met the criteria of authorship as outlined in the International Committee of Medical Journal Editors and approved this manuscript for submission. Specific contributions were as follows: The conception or design of the work and the interpretation of the data for the work were done by TH, DT, YK, and MA; acquisition and revising the work critically for important intellectual content: TH, DT, YK, IS, NY, and MA; analysis: TH; and drafting the work: YT, TH, DT, YK, and MA. The final approval of the version to be published and the agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved were given by all the authors.

### Conflicts of Interest

None declared.

### References

1. Hassan SJ, Weymuller EA. Assessment of quality of life in head and neck cancer patients. *Head Neck* 1993;15(6):485-496 [doi: [10.1002/hed.2880150603](https://doi.org/10.1002/hed.2880150603)] [Medline: [8253555](https://pubmed.ncbi.nlm.nih.gov/8253555/)]



2. Mehanna HM, Morton RP. Does quality of life predict long-term survival in patients with head and neck cancer? *Arch Otolaryngol Head Neck Surg* 2006;132(1):27-31 [[FREE Full text](#)] [doi: [10.1001/archotol.132.1.27](https://doi.org/10.1001/archotol.132.1.27)] [Medline: [16415425](#)]
3. Leipzig B, Suen JY, English JL, Barnes J, Hooper M. Functional evaluation of the spinal accessory nerve after neck dissection. *Am J Surg* 1983;146(4):526-530 [doi: [10.1016/0002-9610\(83\)90246-5](https://doi.org/10.1016/0002-9610(83)90246-5)] [Medline: [6625099](#)]
4. Dijkstra PU, van Wilgen PC, Buijs RP, Brendeke W, de Goede CJ, Kerst A, et al. Incidence of shoulder pain after neck dissection: a clinical explorative study for risk factors. *Head Neck* 2001;23(11):947-953 [doi: [10.1002/hed.1137](https://doi.org/10.1002/hed.1137)] [Medline: [11754498](#)]
5. Hillel AD, Kroll H, Dorman J, Medieros J. Radical neck dissection: a subjective and objective evaluation of postoperative disability. *J Otolaryngol* 1989;18(1):53-61 [Medline: [2921788](#)]
6. Köybasioglu A, Tokcaer AB, Uslu S, Ileri F, Beder L, Ozbilen S. Accessory nerve function after modified radical and lateral neck dissections. *Laryngoscope* 2000;110(1):73-77 [[FREE Full text](#)] [doi: [10.1097/00005537-200001000-00014](https://doi.org/10.1097/00005537-200001000-00014)] [Medline: [10646719](#)]
7. Vartanian JG, Carvalho AL, Toyota J, Kowalski ISG, Kowalski LP. Socioeconomic effects of and risk factors for disability in long-term survivors of head and neck cancer. *Arch Otolaryngol Head Neck Surg* 2006;132(1):32-35 [[FREE Full text](#)] [doi: [10.1001/archotol.132.1.32](https://doi.org/10.1001/archotol.132.1.32)] [Medline: [16415426](#)]
8. Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC. Opioids compared to placebo or other treatments for chronic low-back pain. *Cochrane Database Syst Rev* 2013(8):CD004959 [[FREE Full text](#)] [doi: [10.1002/14651858.CD004959.pub4](https://doi.org/10.1002/14651858.CD004959.pub4)] [Medline: [23983011](#)]
9. Brogly N, Wattier JM, Andrieu G, Peres D, Robin E, Kipnis E, et al. Gabapentin attenuates late but not early postoperative pain after thyroidectomy with superficial cervical plexus block. *Anesth Analg* 2008;107(5):1720-1725 [[FREE Full text](#)] [doi: [10.1213/ane.0b013e318185cf73](https://doi.org/10.1213/ane.0b013e318185cf73)] [Medline: [18931238](#)]
10. Himmelseher S, Durieux ME. Ketamine for perioperative pain management. *Anesthesiology* 2005;102(1):211-220 [[FREE Full text](#)] [doi: [10.1097/00000542-200501000-00030](https://doi.org/10.1097/00000542-200501000-00030)] [Medline: [15618805](#)]
11. Dualé C, Guastella V, Morand D, Cardot JM, Aublet-Cuvelier B, Mulliez A, et al. Characteristics of the neuropathy induced by thoracotomy: a 4-month follow-up study with psychophysical examination. *Clin J Pain* 2011;27(6):471-480 [doi: [10.1097/AJP.0b013e31820e12d4](https://doi.org/10.1097/AJP.0b013e31820e12d4)] [Medline: [21368665](#)]
12. Gottrup H, Andersen J, Arendt-Nielsen L, Jensen TS. Psychophysical examination in patients with post-mastectomy pain. *Pain* 2000;87(3):275-284 [doi: [10.1016/S0304-3959\(00\)00291-8](https://doi.org/10.1016/S0304-3959(00)00291-8)] [Medline: [10963907](#)]
13. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. *Lancet* 2006;367(9522):1618-1625 [doi: [10.1016/S0140-6736\(06\)68700-X](https://doi.org/10.1016/S0140-6736(06)68700-X)] [Medline: [16698416](#)]
14. Hamada H, Moriwaki K, Shiroyama K, Tanaka H, Kawamoto M, Yuge O. Myofascial pain in patients with postthoracotomy pain syndrome. *Reg Anesth Pain Med* 2000;25(3):302-305 [doi: [10.1016/s1098-7339\(00\)90016-6](https://doi.org/10.1016/s1098-7339(00)90016-6)] [Medline: [10834788](#)]
15. Kairaluoma PM, Bachmann MS, Rosenberg PH, Pere PJ. Preincisional paravertebral block reduces the prevalence of chronic pain after breast surgery. *Anesth Analg* 2006;103(3):703-708 [[FREE Full text](#)] [doi: [10.1213/01.ane.0000230603.92574.4e](https://doi.org/10.1213/01.ane.0000230603.92574.4e)] [Medline: [16931684](#)]
16. Gottschalk A, Smith DS, Jobes DR, Kennedy SK, Lally SE, Noble VE, et al. Preemptive epidural analgesia and recovery from radical prostatectomy: a randomized controlled trial. *JAMA* 1998;279(14):1076-1082 [[FREE Full text](#)] [doi: [10.1001/jama.279.14.1076](https://doi.org/10.1001/jama.279.14.1076)] [Medline: [9546566](#)]
17. Lavand'homme PM, Roelants F, Waterloos H, Collet V, De Kock MF. An evaluation of the postoperative antihyperalgesic and analgesic effects of intrathecal clonidine administered during elective cesarean delivery. *Anesth Analg* 2008;107(3):948-955 [[FREE Full text](#)] [doi: [10.1213/ane.0b013e31817f1595](https://doi.org/10.1213/ane.0b013e31817f1595)] [Medline: [18713912](#)]
18. Coderre TJ, Xanthos DN, Francis L, Bennett GJ. Chronic Post-Ischemia Pain (CPIP): a novel animal model of Complex Regional Pain Syndrome-type I (CRPS-I; reflex sympathetic dystrophy) produced by prolonged hindpaw ischemia and reperfusion in the rat. *Pain* 2004;112(1-2):94-105 [doi: [10.1016/j.pain.2004.08.001](https://doi.org/10.1016/j.pain.2004.08.001)] [Medline: [15494189](#)]
19. Ballas SK, Gupta K, Adams-Graves P. Sick cell pain: a critical reappraisal. *Blood* 2012;120(18):3647-3656 [[FREE Full text](#)] [doi: [10.1182/blood-2012-04-383430](https://doi.org/10.1182/blood-2012-04-383430)] [Medline: [22923496](#)]
20. Rüger LJ, Irnich D, Abahji TN, Crispin A, Hoffmann U, Lang PM. Characteristics of chronic ischemic pain in patients with peripheral arterial disease. *Pain* 2008;139(1):201-208 [doi: [10.1016/j.pain.2008.03.027](https://doi.org/10.1016/j.pain.2008.03.027)] [Medline: [18472216](#)]
21. Takeda D, Hasegawa T, Ueha T, Imai Y, Sakakibara A, Minoda M, et al. Transcutaneous carbon dioxide induces mitochondrial apoptosis and suppresses metastasis of oral squamous cell carcinoma in vivo. *PLoS One* 2014;9(7):e100530 [[FREE Full text](#)] [doi: [10.1371/journal.pone.0100530](https://doi.org/10.1371/journal.pone.0100530)] [Medline: [24988190](#)]
22. Saito I, Hasegawa T, Ueha T, Takeda D, Iwata E, Arimoto S, et al. Effect of local application of transcutaneous carbon dioxide on survival of random-pattern skin flaps. *J Plast Reconstr Aesthet Surg* 2018;71(11):1644-1651 [doi: [10.1016/j.bjps.2018.06.010](https://doi.org/10.1016/j.bjps.2018.06.010)] [Medline: [30031765](#)]
23. Ueha T, Oe K, Miwa M, Hasegawa T, Koh A, Nishimoto H, et al. Increase in carbon dioxide accelerates the performance of endurance exercise in rats. *J Physiol Sci* 2018;68(4):463-470 [[FREE Full text](#)] [doi: [10.1007/s12576-017-0548-6](https://doi.org/10.1007/s12576-017-0548-6)] [Medline: [28601950](#)]

24. Oe K, Ueha T, Sakai Y, Niikura T, Lee SY, Koh A, et al. The effect of transcutaneous application of Carbon Dioxide (CO<sub>2</sub>) on skeletal muscle. *Biochem Biophys Res Commun* 2011;407(1):148-152 [doi: [10.1016/j.bbrc.2011.02.128](https://doi.org/10.1016/j.bbrc.2011.02.128)] [Medline: [21371433](https://pubmed.ncbi.nlm.nih.gov/21371433/)]
25. Sakai Y, Miwa M, Oe K, Ueha T, Koh A, Niikura T, et al. A novel system for transcutaneous application of carbon dioxide causing an "artificial Bohr effect" in the human body. *PLoS One* 2011;6(9):e24137 [FREE Full text] [doi: [10.1371/journal.pone.0024137](https://doi.org/10.1371/journal.pone.0024137)] [Medline: [21931656](https://pubmed.ncbi.nlm.nih.gov/21931656/)]
26. Yatagai N, Hasegawa T, Kyotani K, Noda T, Amano R, Saito I, et al. Exploratory clinical trial to evaluate the efficacy and safety of carbon dioxide paste in healthy people. *Medicine (Baltimore)* 2022;101(29):e29511 [FREE Full text] [doi: [10.1097/MD.00000000000029511](https://doi.org/10.1097/MD.00000000000029511)] [Medline: [35866800](https://pubmed.ncbi.nlm.nih.gov/35866800/)]
27. Inoue H, Nibu KI, Saito M, Otsuki N, Ishida H, Onitsuka T, et al. Quality of life after neck dissection. *Arch Otolaryngol Head Neck Surg* 2006;132(6):662-666 [FREE Full text] [doi: [10.1001/archotol.132.6.662](https://doi.org/10.1001/archotol.132.6.662)] [Medline: [16785413](https://pubmed.ncbi.nlm.nih.gov/16785413/)]
28. Marchin D, Campbell MJ, Tan SB, Tan SH. *Sample Size Tables for Clinical Studies*, Third Edition. Chichester, UK: Wiley-Blackwell; 2009.
29. Bindu S, Mazumder S, Bandyopadhyay U. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and organ damage: a current perspective. *Biochem Pharmacol* 2020;180:114147 [FREE Full text] [doi: [10.1016/j.bcp.2020.114147](https://doi.org/10.1016/j.bcp.2020.114147)] [Medline: [32653589](https://pubmed.ncbi.nlm.nih.gov/32653589/)]
30. El-Mashad AER, El-Mahdy H, El Amrousy D, Elgendy M. Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. *Eur J Pediatr* 2017;176(2):233-240 [FREE Full text] [doi: [10.1007/s00431-016-2830-7](https://doi.org/10.1007/s00431-016-2830-7)] [Medline: [28004188](https://pubmed.ncbi.nlm.nih.gov/28004188/)]

## Abbreviations

**CO<sub>2</sub>:** carbon dioxide  
**CRF:** case report form  
**EDC:** electronic data capture  
**jRCT:** Japan Registry of Clinical Trials  
**QOL:** quality of life  
**REDCap:** Research Electronic Data Capture  
**VAS:** visual analog scale

*Edited by A Mavragani; submitted 04.07.23; peer-reviewed by D Takahashi, S Sakakibara; comments to author 13.10.23; revised version received 19.10.23; accepted 20.10.23; published 13.11.23*

### *Please cite as:*

Tadokoro Y, Takeda D, Saito I, Yatagai N, Kakei Y, Akashi M, Hasegawa T  
*The Efficacy of Carbon Dioxide Paste in Alleviating Pain in Patients After Neck Dissection: Protocol for a Double-Blinded, Randomized Controlled Trial*  
*JMIR Res Protoc* 2023;12:e50500  
URL: <https://www.researchprotocols.org/2023/1/e50500>  
doi: [10.2196/50500](https://doi.org/10.2196/50500)  
PMID: [37955944](https://pubmed.ncbi.nlm.nih.gov/37955944/)

©Yoshiaki Tadokoro, Daisuke Takeda, Izumi Saito, Nanae Yatagai, Yasumasa Kakei, Masaya Akashi, Takumi Hasegawa. Originally published in *JMIR Research Protocols* (<https://www.researchprotocols.org/>), 13.11.2023. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in *JMIR Research Protocols*, is properly cited. The complete bibliographic information, a link to the original publication on <https://www.researchprotocols.org/>, as well as this copyright and license information must be included.